Home

GW is the global leader in developing cannabinoid-based medicines. Cannabidiol (approved by FDA as Epidiolex® in the United States) is in development to treat certain rare and catastrophic forms of childhood-onset epilepsy that currently have few treatment options.

Healthcare Professionals: Learn more about cannabidiol (CBD) development

GW’s vision is to be the global leader in prescription cannabinoid medicines, developing and commercializing pharmaceutical products which address clear unmet needs.
Justin Gover, Chief Executive Officer
GW's vision pic

RECENT NEWS

Nov 06, 2018
LONDON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 27 November, 2018 its
Nov 01, 2018
- Medication indicated for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies - - Comprehensive support program available for eligible patients - LONDON and CARLSBAD, Calif., Nov.
Oct 05, 2018
LONDON and CARLSBAD, Calif. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today